Menarini strengthens its presence in aesthetic dermatology in India
Menarini India Private Limited (‘Menarini India’), part of the Menarini Group, the world’s largest Italian biopharmaceutical company and a global leader in dermatology and aesthetics solutions worldwide, recently announced its expansion into the Indian aesthetics market. With a strong commitment…
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for…
Insights From HumanFirst Show Breadth of Pharmaceutical Investment in AI/ML and Digital Endpoints in Clinical Trials
Regulators are increasingly approving AI-powered endpoints using digital health technologies (DHTs) in drug development. To quantify this trend, HumanFirst, life science’s first cloud-based platform for precision measures, today released an industry analysis showing just how many pharmaceutical sponsors have used…
Empowering Pharmaceutical Companies in Chronic Disease Research and Identifying Unmet Needs says Disease Landscape Insights
Chronic diseases are long term ailments that progress over time. They are non-communicable in nature and can lead to severe health complications if left undetected and untreated. Chronic disease prevalence has been increasing dramatically across the globe. Unhealthy lifestyle choices,…
WuXi Vaccines Launches Its First Vaccines CDMO Site in China
WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China. The opening will add drug substance and drug product capacity, with end-to-end…
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO (contract testing, development and manufacturing organization) to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and…
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that on September 19, 2023, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the…
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs containing fluorouracil and platinum for the…
‘LEQEMBI® Intravenous Infusion’ approved for the treatment of Alzheimer’s disease in Japan
BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that “LEQEMBI® Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to…
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
Pierre Fabre Laboratories and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets. Under the terms of the agreement, Vernalis will use its…
